Introduction
The p53 tumor suppressor gene controls cellular responses to DNA damage and forms a critical link to downstream effectors of growth arrest or cell death (Agarwal et al., 1998; el-Deiry, 1998; Lakin and Jackson, 1999; Caspari, 2000) . We have previously used mouse models to show that the p53 gene protects mice in vivo from the tumorigenic effects of radiation exposure. A single dose of 4 Gy radiation decreases the average lifespan of p53 heterozygous knockout mice by about 35 weeks, without affecting the lifespan of control wildtype animals (Kemp et al., 1994) . Most radiationinduced tumors from p53 þ /À mice show loss of the remaining wild-type allele, but the nature of the other genetic events required for tumor progression remains unknown. In order to identify other tumor suppressor loci involved in radiation-induced cancer, we have previously conducted a genome wide screen for loss of heterozygosity (LOH) using both microsatellite analysis and comparative genomic hybridization on microarrays (CGH arrays) (Cai et al., 2002) . This study revealed a number of frequent genetic changes involving several mouse chromosomes, including chromosome 19, which has also been suggested by other groups to contain a lymphoma tumor suppressor gene as well as a locus that controls lymphoma susceptibility (Santos et al., 2002) . We demonstrate here that the detailed LOH pattern on chromosome 19 indicates the presence of at least three separate regions of deletion, one of which contains the Pten tumor suppressor gene.
The Pten gene is an important tumor suppressor gene that shows both germline and somatic mutations in a variety of human tumor types (Leslie and Downes, 2002; Waite and Eng, 2002) . The Pten protein acts as a lipid phosphatase that can inhibit the activation of the serinethreonine kinase Akt, leading to attenuation of survival signals and apoptosis (Leslie and Downes, 2002; Waite and Eng, 2002) . The Pten gene has previously been shown to be activated by radiation (Virolle et al., 2001) , and is involved in a complex network of interactions with p53 Oren et al., 2002) . Mutational analysis of the PTEN gene in human tumors has demonstrated that the overall mutation frequency is quite low, that LOH is not often accompanied by mutation of the remaining wild-type allele, and that in some cases intragenic mutations are detected in one allele, with retention and expression of the remaining wild-type allele (Ali et al., 1999) . This data suggested that Pten is a haploinsufficient tumor suppressor gene, since loss of only one copy appeared to be required for tumor development. Pten heterozygous knockout mice (Pten þ /À) were reported to show increased susceptibility to prostate cancer induced by an SV40 T transgene, but in the tumors the wild-type allele of Pten was frequently lost, a result that would not be expected if Pten functions as a haploinsufficient tumor suppressor (Fero et al., 1998; Tang et al., 1998) . To date, no intragenic heterozygous Pten mutations of the kind found in human cancers have been reported in primary mouse tumors. Our studies show that Pten haploinsufficiency induced by whole chromosome loss or by small deletions, some within the Pten gene, is a common feature of radiation-induced lymphoma development. In addition, compound heterozygosity for both p53 and Pten causes a large increase in susceptibility to radiation-induced lymphoma. The results have important implications for our understanding of the combinatorial effects of genetic changes in tumor development.
Results
A substantial proportion of lymphomas induced in p53 þ /À mice by radiation exposure show LOH on chromosome 19 (Santos et al., 2001; Cai et al., 2002) . To determine whether LOH on this chromosome is dependent on p53 status, we carried out a backcross between p53 þ /À (Mus spretus Â 129/Sv) F1 hybrid mice and p53À/À 129/Sv mice to generate animals that were either p53 þ /À or p53À/À, but were heterozygous Mus spretus/129/Sv at multiple loci. This genotype enabled us to investigate LOH on chromosome 19 by microsatellite analysis of tumors from both p53 heterozygous and null animals. This analysis demonstrated that of the 61 tumors investigated from p53 null mice, 51.4% showed LOH at multiple markers on chromosome 19, a similar proportion to that detected in tumors from p53 þ /À mice. We conclude that the critical gene(s) on this chromosome do not depend on p53 for their potential tumor suppressor activity.
Sublocalization of LOH on chromosome 19
By a more detailed inspection of the patterns of microsatellite allele loss in these tumors, we found at least three independent loci on chromosome 19. While most tumors showed large-scale losses involving the whole chromosome, several showed discrete patterns of loss that implicated at least three separate regions of chromosome 19, one between markers D19Mit86 and D19MAD11, one between D19Mit13 and D19MAD9, and the other located more proximally near D19Mit82 (Figure 1 and data not shown).
The smallest interval identified from our initial screen was a 0.3 Mb region between D19Mit13 and D19MAD9. This interval encodes only four transcripts as estimated from the Celera and Public databases, that is, Papss2, Pten, and two novel genes (Figure 1 ). We focused on the Pten gene initially because of its known activity as a tumor suppressor gene for a variety of tumor types including lymphomas (Gronbaek et al., 1998; Butler et al., 1999; Dahia et al., 1999; Herranz et al., 2000; Izumoto et al., 2001; Frisk et al., 2002; Kurose et al., 2002; Shin et al., 2002) , and its possible role in radiation sensitivity (Wick et al., 1999) .
A previous study of radiation-induced lymphoma in p53 wild-type mice suggested that a large region of chromosome 19 may undergo methylation-based silencing of a number of genes, including Pten, but found no Figure 1 Detailed analysis of LOH patterns on chromosome 19 sublocalized three regions, denoted by the lines at the bottom of the figure. The four transcripts within locus 2 are shown at the top. Physical mapping of markers and genes is based on the Celera database. We did not show the partial loss not related to locus 2, loss of whole chromosome, and no loss in tumors in the figure evidence for intragenic mutations in any gene on this chromosome (Santos et al., 2001) . To determine whether Pten was inactivated by methylation leading to loss of expression, reverse transcriptase (RT)-PCR was used to detect Pten transcripts in 27 tumors from p53 þ /À (C57BL/6 Â 129) F1 mice (10 of which showed LOH in Pten) and 15 tumors from p53À/À (C57BL/6 Â 129) F1 mice (six with LOH at the Pten locus) ( Table 1) . As shown in Figure 2a , Pten was expressed in all tumors, but different sized PCR products were seen in tumors 11, 12, 16, 20, 25 from p53 þ /À mice, and in tumor 5 from a p53À/À mouse, indicating the presence of splice variants or intragenic deletions within the Pten gene in these tumors. Subsequent sequencing of all of these RT-PCR fragments confirmed that tumor no. 20 had a small deletion of 33 nucleotides within exon 5, while the other tumors were missing whole exon sequences (Table 1 ). The deletion within exon 5 in tumor no. 20 was confirmed by sequencing of genomic DNA, but attempts to generate fragments spanning the deletions in other tumors using exon primers were unsuccessful, possibly because the breakpoints occur within the large introns of the Pten gene. It remains formally possible that some of the tumors have mutations in splice donor or acceptor sites, but no evidence for this mechanism has as yet been obtained. In two cases (one each from p53 þ /À and p53À/À mice), tumors with LOH also had mutations in the remaining wild-type Pten allele, but in the majority of cases, tumors with LOH appeared to retain expression of a wild-type allele. In order to demonstrate Pten expression at the protein level, Western blots were performed with tumor lysates from several of the tumors in Table 1 (Figure 2b ). This analysis showed that tumors showing LOH with retention of a wild-type allele continued to express this allele at the protein level. Similarly, the two tumors from p53 þ /À mice that retained both alleles but had acquired mutations leading to loss of exon 6 from one allele, continued to express the wild-type protein.
In a search for point mutations in the Pten coding region, the RT-PCR products from all of the other tumors with normal PCR fragment sizes were sequenced. Surprisingly, none of these tumors showed evidence of mutations in the Pten gene, regardless of LOH status. In summary, although more than 50% of tumors from p53 þ /À or p53À/À mice had lost one allele of Pten, six of 42 tumors that were sequenced had intragenic mutations, and in only two of these was the mutation accompanied by loss of the wild-type allele. The gene that lies closest to Pten on chromosome 19, mCG13040, was also sequenced in its entirety from all 42 tumors, but no evidence of any point mutations was found (data not shown). All tumors showing LOH or heterozygous intragenic mutations in Pten continued to express the wild-type allele, compatible with genuine haploinsufficiency for this tumor suppressor gene.
Radiation-induced tumorigenesis in p53À and
Pten-deficient mice The results described above suggested that Pten functions as a haploinsufficient lymphoma suppressor gene, Pten and p53 in radiation-induced lymphoma development J-H Mao et al mice (Fero et al., 1998; Tang et al., 1998) . In order to investigate this question, 26 Pten þ /À, 25 p53 þ /À, 19 Pten þ /Àp53 þ /À, 24 p53À/À, and 35 wild-type mice were exposed to a single dose of 4 Gy whole body girradiation at 5 weeks of age. Only three wild-type mice developed tumors within 60 weeks. In contrast, there was a dramatic decrease in latency of tumor development in both p53 and Pten heterozygous mice (P-value o0.0001). Surprisingly, Pten heterozygous mice were just as sensitive as p53 heterozygotes to induction of tumors by radiation. Previous results have also demonstrated sensitivity of Pten single heterozygotes to radiation-induced lymphoma (Suzuki et al., 1998) . Surprisingly, however, p53/Pten double heterozygous mice developed tumors much earlier than single heterozygous mice (P-value o0.0001, Figure 3 ), and were equivalent to p53 null mice in radiation sensitivity. Further PCR analysis of the tumor DNA showed that the remaining wild-type allele of Pten was lost in the majority of tumors. This seemed surprising in view of the arguments presented above for a haploinsufficient role for Pten, and additional studies were carried out to determine the mechanism of allele loss in these tumors. Interestingly, while 18/31 tumors from Pten þ / þ mice showed partial losses of chromosome 19 that were localized in three separate regions, LOH in tumors from the Pten þ /À and Pten þ /Àp53 þ /À mice invariably involved the whole chromosome (Figure 4 ). Our interpretation of these data is that the chromosome 19 LOH seen in tumors from Pten heterozygous mice is in fact driven not by requirement for complete loss of Pten, but by loss of additional tumor suppressor genes on this chromosome.
Discussion
The data presented in this report underline the potent effects of loss of a single copy of the Pten tumor suppressor gene, particularly in the context of p53 deficiency. We have shown that LOH of the Pten gene occurs in more than 50% of radiation-induced thymic lymphomas, but mutation or homozygous deletion of the Pten gene is detected in only about 14% of tumors. Importantly, intragenic heterozygous Pten deletions were detected in a subset of tumors, and in these cases the remaining allele of Pten continued to be expressed, indicating that Pten did not undergo methylationmediated gene silencing. Our results are different from a previous report by Santos et al. (2001) , where they found loss of Pten expression in radiation-induced thymic lymphomas (but no evidence of point mutations or small deletions). The reasons for this discrepancy are not clear, but may be due to the use of different mouse strains in the two studies. The results we have described for mouse lymphoma development -frequent LOH at the Pten locus but relatively rare intragenic mutations accompanied by retention of expression -are consistent with a haploinsufficient role for Pten in mouse lymphoma development. Similar conclusions have been reached from several studies of human cancers, for example, gastric tumors in which LOH was frequently detected, but mutational inactivation of the remaining allele was rare. In another study of gastric cancer, a relatively low frequency of intragenic mutations was also detected, and these were clustered around exons 2-6, where the majority of mutations were found in our study of mouse lymphomas (Table 1 ). The significance of this clustering remains unclear.
In two lymphomas investigated, full inactivation of Pten was seen by intragenic mutation and loss of the remaining allele, suggesting that in some cases complete Pten loss is important for tumor progression. However, our analysis indicates that there are several regions of deletion on chromosome 19, only one of which contains the Pten gene, and it is possible that LOH of the wild-type allele is in fact due to the presence of these additional driver genes on this chromosome. Loss of these additional genes may also contribute to the chromosome 19 LOH seen in tumors from Pten þ /À and p53 þ /ÀPten þ /À mice. Interestingly, tumors that showed loss of the wild-type Pten allele in these cases had complete loss of the whole chromosome rather than intragenic deletions (Figure 4) . Further studies will be necessary to identify these additional chromosome 19 genes and their roles in tumor development.
A previous study of prostate tumor development in Pten heterozygous mice also concluded that Pten plays a haploinsufficient role in tumor development, but comparison of this study with the results of the present investigation reveals some interesting differences. Although loss of one functional Pten allele was found in 68% of prostate tumors from Pten þ /À mice and in 47.4% of tumors from wild-type mice, no evidence for any specific intragenic mutations was found in any of these tumors. To our knowledge, no examples exist of intragenic mutations in any mouse (Kwabi-Addo et al., 1998) or rat (Sjoling et al., 2003) models involving LOH at the Pten locus. The situation we have seen in mouse lymphomas more closely resembles that seen in human tumors, in that we see a proportion of small localized changes within the Pten gene, but in only rare cases are these homozygous.
We have also found that Pten heterozygous mice, like p53 heterozygous mice, are susceptible to radiationinduced tumorigenesis. There is no difference in tumor latency between p53 and Pten heterozygous mice after a single dose of 4 Gy g-irradiation, and even more surprisingly the latency of radiation-induced tumorigenesis in p53/Pten double heterozygous mice is equivalent to that of p53 null mice. p53 and Pten are functionally related. Recently, it has been reported that Pten protects p53 from degradation mediated by Mdm2 , and in turn p53 can positively upregulate Pten gene expression at the transcriptional level (Stambolic et al., 2001) . Subsequent studies by Freeman et al. (2003) provided evidence for a direct role for Pten in the stabilization of the p53 protein. The complexity of the interactions between these two genes was further underlined by the demonstration by Kurose et al. (2002) that mutually exclusive mutations in p53 and Pten genes are found in epithelial and stromal components of some human tumors. These results offer an additional explanation for the synergistic increase in tumor susceptibility in mice with partial germline deficiency of both genes. The p53 deficiency in the target cell compartment in the thymus may be complemented by Pten deficiency in stromal cells within the tumor microenvironment and vice versa. In other words, the interaction between these two important genes may take place at both cell autonomous and noncell autonomous levels.
Our studies on radiation-induced tumor development in the Pten/p53 double heterozygous mice also shed light on cooperation between somatic genetic events during tumor development. The fact that mice with only one copy of each gene are so highly predisposed to lymphoma development (equivalent to p53 null mice) suggests that if loss of chromosome 17p containing one copy of the p53 gene occurs in a human tumor, subsequent loss of chromosome 10q could have a synergistic effect on genetic instability or some other property that contributes to tumor progression, without requiring the acquisition of inactivating mutations in either gene. Studies of possible concordance between LOH on 10q and on 17p in the absence point inactivating mutations are presently in progress to investigate these questions.
Materials and methods
Mice and tumour induction p53 and Pten single or double heterozygous KO mice were generated by crossing Pten þ /À heterozygous KO (C57BL/6 background, obtained from Dr PP Pandolfi (Di Cristofano et al., 1998) with p53 þ /À heterozygous KO (129/Sv), purchased from Jax Laboratories. The 5-week-old mice of both sexes were exposed to a single dose of 4 Gy whole-body irradiation and monitored daily until moribund, then killed and autopsied.
Sublocalizing LOH on chromosome 19 by PCR of microsatellite markers LOH was determined by PCR of microsatellite markers, with normal and tumor DNA from the same mice. Map position was based on the Celera database.
PCR primer pairs for markers were purchased from Qiagen Operon (www.operon.com). PCR reactions were set up in a total volume of 20 ml, containing 2 ml of 10 Â PCR buffer (Bioline), 1.6 ml of 2.5 mM dNTPs (Pharmacia Biosystem Ltd), 1 ml (6.6 mM) of each primer, 0.6 ml of 50 mM MgCl 2 (Bioline), 11.7 ml dH 2 O, 0.1 ml Taq polymerase (Bioline), and 2 ml (40 ng/ ml) tumor or normal tissue DNA. Amplifications were initially denatured at 941C for 3 min, followed by 35 cycles at 941C for 30 s, 551C or 521C for 30 s and 721C for 30 s, and then a final incubation at 721C for 5 min. The PCR products were then mixed with loading buffer and electrophoresed in 4% (3% NuSieve/1% agarose) agarose gel with 0.5 mg/ml ethidium bromide, photographed and saved in image file for analysis of density of bands.
Expression and mutation analysis of Pten and a novel gene (mCG13040)
Total RNA was extracted from tumor tissue samples with TRIzol Reagent (Invitrogen Life Technologies). RT-PCR were performed using Thermoscriptt RT-PCR system (GIB-CO-BRL) according to the manufacturer's instructions.
Expression and mutation analysis of the Pten gene was performed by PCR amplification of cDNA from thymic lymphomas by using the following primers: Pten1F, 5 0 -CATCTCTCTCCTCCTTTTTCTTCA-3 0 ; Pten1R, 5 0 -CAAA-CATCATCTTGTGAAACAGC-3 0 ; Pten2F, 5 0 -GGCAAATT TTTAAAGGCACAAG-3 0 ; Pten2R, 5 0 -AAGTTGAACTGC-TAGCCTCTGG-3 0 ; Pten3F, 5 0 -ACTTTGAGTTCCCTCA GCCA-3 0 ; Pten3R, 5 0 -TTCATGGTATTTTATCCCTCTT GA-3 0 . The primers for the novel gene (mCG13040): N1F, 5 0 -CTCGTCCATTGAGTCGGAAT-3 0 ; N1R, 5 0 -AACAGCAG-CAGCCAGTTTTT-3 0 ; N2F, 5 0 -CTACTGCAGCCTCCAAA AGG-3 0 ; N2R, 5 0 -GCATCCCGACACATTTCTTT-3 0 ; N3F, 5 0 -TAATGGGAGCTACCAATCGC-3 0 ; N3R, 5 0 -CAGTTTC CTCCGCATGATTT-3 0 . PCR products were gel-purified and sequenced by the UCSF genome CORE.
Western blotting
Total protein extracts were prepared from tumor tissue samples with RIPA lysis buffer. For Western blots, 30 mg of protein extract per lane was electrophoresed, transferred to PVDF membrane (Millipore), and immunoblotted overnight at 41C with a 1 : 500 dilution of anti-PTEN antibody (Santa Cruz), and as control the same membrane was stripped and immunoblotted again with 1 : 10 000 dilution of anti-b-actin antibody (Sigma). The membranes were washed and treated with rat anti-mouse IgG k-chain secondary antibody (1 : 10 000) conjugated to horseradish peroxidase (Amersham Pharmacia). The antigen-antibody reaction was visualized by using an enhanced chemiluminesence assay ECL (Amersham Pharmacia) and exposure to enhanced chemiluminesence film.
Statistical analysis
Kaplan-Meier method was used to compare the survival time postradiation between different groups of genotype of mice by SPSS statistical package. The P-values are presented in the text.
